TMCI · Treace Medical Concepts, Inc.
$4.00
-0.05 (-1.23%)
At close · Jul 24
Market Cap
$259.49M
Shares
64.87M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.05
Open$3.87
Day$3.85–4.06
52W$1.17–7.78
Avg vol 30d941K
Short int1.8M · 2.8% float · 3.6d
Short vol40%
Last earningsMay 8, 2026
DataApr 2021–Jul 2026
Filing10-Q · May 8
Up next
Next earnings call
Aug 7, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+31%
above
Price vs 50-day avg
+7%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
44%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+76%
trailing
YTD return
+65%
this year
Relative strength
+70%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Distributing
19 of 117 funds reported for Jun 30 · net -14.0K sh shares · +3 new
Insider flow
Accumulating
Net +$993.2K over 90 days · 0% sells
Short interest
Rising
2.84% of float · ▲ +5.5% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
117 holders — near 3-yr low, contrarian setup
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
Gross margin
80%
contracting
EPS growth
−3%
Y/Y
Free cash flow
$-29.5M
Balance sheet
$46.7M
net debt
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 8, 2026
full-year 2026
Revenue
Raised
$202M – $212M
prior FY $212.69M
midpoint −2.7% Y/Y
Cash usage
Initiated
up to 50%
full year 2026
Adjusted EBITDA
Non-GAAP
Initiated
$-6M – $-4M
Guided vs delivered
· last 1 settled
2025 revenue
full year 2025
guided $211M – $213M
$212.69M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+31%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
44%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Distributing
19 of 117 funds reported for Jun 30 · net -14.0K sh shares · +3 new
Insider flow
Accumulating
Net +$993.2K over 90 days · 0% sells
Short interest
Rising
2.84% of float · ▲ +5.5% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
117 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1
Now $4 · 44%
52-wk high $8
vs 200-day avg +31%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$5.5M | first quarter 2026 | — |
|
|
|||
| Active surgeons | 3,337 | full-year 2025 | — |
| Granted patents | 135 | full-year 2025 | — |
| Net new active surgeons | 202 | full-year 2025 | — |
| Pending patent applications | 199 | full-year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TMCI
this stock
Treace Medical Concepts, Inc.
|
$259.49M | +65.3% | +1.6% | — | 2.8% |
|
ABT
Abbott Laboratories
|
$179.51B | -19.2% | +5.7% | 28.9 | 1.4% |
|
SYK
Stryker Corp
|
$126.60B | -9.0% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$106.51B | -13.9% | +8.4% | 22.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.77B | -54.3% | +5.5% | 18.5 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TMCI | -8.6% | -1.9% | +76.1% | +1.8% | +65.3% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -6.9% | -2.6% | +69.7% | +2.9% | +57.1% |